HEALTH TECHNOLOGY

Redox and Intelligent Medical Objects Partnering to Augment Healthcare Data

Redox Inc. | October 18, 2022 | Read time : 02:00 min

Redox and Intelligent

Redox, the company setting the stage for composable healthcare, has partnered with Intelligent Medical Objects, a healthcare data enablement company to standardize clinical data from diverse systems into consistent, structured, clinically validated terminology including comprehensive mapping to major global coding systems. Now healthcare companies can spend more time building improved patient and clinician experiences by eliminating the lengthy and taxing process of combining multiple point solutions.

This announcement comes directly after last week's launch of API Actions, a modular way for healthcare companies to build out their ideal workflows. This present partnership between IMO and Redox benefits any healthcare company that receives clinical problem or diagnosis data from multiple organizations. As a result, these are further able to enrich healthcare data using consistent terminology across all data standards, formats, and workflows with a single Redox API.

"Redox is dedicated to making sure that healthcare data can empower builders to create new experiences for patients and providers. We want to be clear that composable healthcare is a practice of bringing together the best technologies to produce the best solutions, and we're glad to be doing so with IMO."

Redox CEO Luke Bonney

"Clinical patient data is a powerful resource in healthcare. IMO partnering with Redox will accelerate the ability for healthcare companies to leverage that data to create better outcomes for doctors and patients," said IMO CEO Ann Barnes.

Redox will leverage IMO's technology to standardize healthcare data for its customers. Using IMO Precision Normalize will allow Redox to accelerate data normalization for its hospital and software vendor clients. This lets healthcare technology companies spend more time building powerful solutions by eliminating the lengthy and costly process of cleaning and standardizing messy clinical data.

SNOMED® is a registered trademark of International Health Terminology Standards Development Organisation

About Redox 
Payers, providers, digital health companies, and other healthcare entities use Redox to produce differentiated experiences for patients and clinicians. Connecting to more than 30,000 healthcare organizations, Redox provides a composable software experience across the healthcare ecosystem. With our single API, product teams are empowered to build whatever they can imagine. Redox accelerates innovations that make healthcare data more useful than ever before.

About IMO
Intelligent Medical Objects is a healthcare data enablement company. From clinical documentation at the point of care to complex approaches to population health management, IMO ensures clinical data integrity and quality—making patient information fit-for-purpose across the healthcare ecosystem. For almost three decades, IMO's footprint in EHRs—across more than 4,500 US hospitals—powers our expert ability to capture and preserve clinical intent wherever and however data is used. Our primary clients span individual doctors and physician groups, hospitals and clinics, large integrated delivery networks, inpatient ORs and surgical centers, global electronic health record providers, health information exchanges, clinical data registries, payers, life sciences companies, and healthcare analytics vendors. 

Spotlight

G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies.

Spotlight

G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies.

Related News

HEALTH TECHNOLOGY, DIGITAL HEALTHCARE

CCS Introduces Scientific Advisory Council to Advance Chronic Care Management

CCS | February 02, 2023

On February 1, 2023, CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced the launch of its Scientific Advisory Council, comprised of four industry leaders who will assist CCS in its commitment to reinventing patient care at home through a more holistic approach. The Council consists of Karmeen Kulkarni, MS, RD, CD, CDCES, BC-ADM; Alexander Ding, MD, MBA; Steven Wittlin, MD; and Francine Kauffman, MD. This announcement follows the appointment of Arti Masturzo, MD, as CCS's first Chief Medical Officer. Over 11% of the US population has been diagnosed with diabetes, which is projected to increase among American youth and young adults. Therefore, there is a great need for innovative technologies, partnerships, and services to fully support people in managing their diabetes. CCS chose to assemble its Scientific Advisory Council and assume a leadership position in redefining how health plans, providers, and employers support their patients and members impacted by costly, debilitating chronic diseases. Additional information about the initial members of the Council is provided below • Alexander Ding, MD, MBA, is a diagnostic and interventional radiologist, Associate VP of Physician Strategy and Medical Affairs for Humana, and an American Medical Association board member. He cultivates physician-health plan relationships and patient empowerment and engagement through digital health. • Karmeen Kulkarni, MS, CD, RD, CDCES, BC-ADM, is a clinical pioneer in diabetes management with over 30 years of experience. She was Abbott's Global Scientific Affairs director for 15 years before starting her consulting firm. Ms. Kulkarni has unique experience integrating devices, technology, coaching, and clinical services to improve outcomes for diabetes patients. • Steven Wittlin, MD, is an endocrinologist, published author, and University of Rochester's Director of Diabetes Services. His experience includes new diabetes treatment procedures that combine best practices in technology, medical devices, and clinical services. • Francine Kaufman, MD, a pediatric endocrinologist, and former American Diabetes Association president, is the Chief Medical Officer at Senseonics, Inc., and previously held that position at Medtronic Diabetes. Dr. Kaufman, a key CCS Strategic Advisory Board member, will also be on the Scientific Advisory Council. About CCS Based in Dallas, Texas, CCS provides collaborative care programs and medical supplies delivered at home for people with chronic conditions, particularly diabetes. As a result, patients have better probabilities of starting and continuing therapy with CCS as their partner, lowering costs and enhancing outcomes. The company serves over 150,000 people in the United States with chronic conditions and delivers over 1.2 million medical products to homes yearly. With over 25 years of experience, CCS has the expertise, data, and relationships to usher in a new era of home-based, proactive chronic care management.

Read More

FUTURE OF HEALTHCARE

Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association

Veradigm | November 23, 2022

Veradigm, a business unit of Allscripts announced The Point of Care Marketing Association a nonprofit organization to support the continued growth of the Point of Care channel through education and advocacy, has welcomed Veradigm to its membership. Veradigm Digital Health Media is the first EHR marketing solution to be accepted as a member of POCMA Stuart Green, Senior Vice President & General Manager, Veradigm has joined POCMA’s board of directors POCMA exists to advocate for the effective use of the point of care communication channel to advance patient healthcare outcomes. Members of the nonprofit point of care industry association work closely with brand, agency, and provider stakeholders to advocate for the channel and promote its positive impact to ensure its continued growth as a vital and innovative segment of healthcare marketing. “POCMA is excited to have Veradigm as a member and the first within the EHR landscape. Veradigm’s platform of reaching HCPs in their workflow makes them an excellent resource for the association and its members. We look forward to their insights and involvement as we grow the POC industry.” POCMA Executive Director, Nicole Divinagracia “At Veradigm, we share in POCMA’s goal of raising healthcare providers’ awareness through innovative point of care marketing channels,” said Stuart Green, Senior Vice President & General Manager, Veradigm. “With our membership, we look forward to contributing to the establishment of industry best practices and building connections with other point-of-care industry leaders and influencers.” About Allscripts Allscripts is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. Some healthcare technology companies deliver clinical data for biopharma and health plans, some help turn that data into insights, others serve healthcare providers directly by providing point-of-care clinical software and patient outreach platforms. Veradigm does it all. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully.

Read More

FUTURE OF HEALTHCARE

BioIntelliSense Joins Polaris Dawn Mission to Advance Understanding of Human Health in Space

BIOINTELLISENSE | November 15, 2022

BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced its partnership with the Translational Research Institute for Space Health (TRISH) to further understanding of human health in space. The BioButton® medical grade wearable device will be used for commercial spaceflight research programs and notably during the upcoming five-day Polaris Dawn mission. This historic mission will be flown by SpaceX and is scheduled to launch after March 2023. Medical and scientific research on human health in space promotes the advancement of translational technologies by adapting known technology for space applications, and by using space-based insights to improve healthcare at home. “BioIntelliSense has proudly gained industry recognition for its innovative and comprehensive portfolio of continuous multi-parameter monitoring solutions for application in the acute care environment, at home settings and now, in the next frontier of space, As a lifelong space exploration enthusiast, it is a tremendous honor to be working with TRISH on health research that can benefit astronauts and crews during commercial space flight and for the BioButton devices to be part of the upcoming Polaris Dawn mission.” -James Mault, MD, founder and CEO of BioIntelliSense The BioButton multi-parameter device is designed to be worn on the upper left chest and will passively capture trending physiologic and movement data from the Polaris Dawn crew during its milestone mission. The future of healthcare is here. Today, the BioIntelliSense Data-as-a-Service (DaaS) platform and clinical intelligence solution is commercially available and rapidly adopted by acute and post-acute providers in the U.S. along with select international markets. TRISH is proud to partner with innovative healthcare technology leaders like BioIntelliSense as we further our understanding of human health in space, Our EXPAND (Enhancing eXploration and ANalog Definition) commercial spaceflight health research platform provides unique opportunities to rapidly test technologies in orbit, as well as collect new datapoints on the health impact of spaceflight for a wider, more diverse population,said James Hury, TRISH Chief Innovation Officer and Deputy Director. BioIntelliSense (Booth #5025) and TRISH (Space Health Pavilion #2636) will be showcasing the BioButton wearable device and clinical intelligence solution at the premier HLTH 2022 conference November 13 – 16 in Las Vegas, NV. ABOUT BIOINTELLISENSE BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The medical-grade BioButton® wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade remote care from in-hospital to home. ABOUT TRANSLATIONAL RESEARCH INSTITUTE for SPACE HEALTH (TRISH) Led by Baylor College of Medicine’s Center for Space Medicine, TRISH is a consortium that includes partners Caltech and MIT. NASA recently awarded the Institute a six-year extension to further its work by delivering disruptive solutions to mitigate biomedical risks for human exploration while advancing terrestrial health technologies.

Read More